Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + methylprednisolone + cytarabine + oxaliplatin
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ESHAOx is a combination chemotherapy regimen consisting of four drugs: etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin. It was developed as a salvage therapy for patients with refractory or relapsed Hodgkin's lymphoma (HL) and aggressive non-Hodgkin's lymphoma (NHL). The regimen substitutes oxaliplatin for cisplatin in the traditional ESHAP protocol to potentially reduce toxicity while maintaining efficacy. The mechanism of action involves multiple pathways: - Etoposide inhibits topoisomerase II, leading to DNA strand breaks. - Methylprednisolone is a corticosteroid that induces apoptosis in lymphoid cells. - Cytarabine is an antimetabolite that inhibits DNA synthesis. - Oxaliplatin forms DNA crosslinks, inhibiting replication and transcription. Clinical studies have shown that ESHAOx has significant antitumor activity with an acceptable safety profile in heavily pretreated lymphoma patients. Common toxicities include neutropenia and thrombocytopenia; non-hematologic toxicities are generally manageable[1][5][6].
- Brand names
- ESHAOx
- Other names
- ESHAOx regimen
02
Targets
GR (Glucocorticoid receptor)POLA1 (DNA polymerase alpha)DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on etoposide + methylprednisolone + cytarabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + methylprednisolone + cytarabine + oxaliplatin.